Bruker (BRKR) Cash Flow Statement

Click line-items for a historical chart and %

Consolidated net income	85.4M
Depreciation and amortization	40.4M
Amortization of deferred financing costs
Write down of inventories to net realizable value
Stock-based compensation	6.8M
Deferred income taxes
Loss on divestiture of business
Other non-cash expense	12.7M
Accounts receivable	15.4M
Inventories	-73.4M
Accounts payable
Customer deposits	-6.5M
Other changes in operating assets and liabilities, net	7.1M
Net cash (used) in provided by operating activities
Acquisitions, net of cash acquired	-1.2M
Purchases of property, plant and equipment	-26M
Net cash used in investing activities
Repayments of revolving lines of credit, net
Repayment of term debt
Payment of deferred financing costs
Proceeds from issuance of common stock, net	10.2M
Changes in restricted cash	600K
Cash payments to noncontrolling interest	-700K
Net cash used in financing activities
Effect of exchange rate changes on cash and cash equivalents
Net change in cash and cash equivalents	11.6M
Cash and cash equivalents at beginning of period	267.1M
Cash and cash equivalents at end of period	278.7M
Issuance of common stock in connection with acquisition of Michrom Bioresources Inc.

Entities mentioned with BRKR

View All Entities